Sirdupla: new LABA/corticosteroid inhaler

Sirdupla (salmeterol/fluticasone) has been launched for use in adults with asthma where a long-acting ß2-agonist and inhaled corticosteroid is appropriate.

Sirdupla (salmeterol/fluticasone) is a bioequivalent alternative to Seretide Evohaler.
Sirdupla (salmeterol/fluticasone) is a bioequivalent alternative to Seretide Evohaler.

The metered-dose inhaler is available in two strengths:

  • 25/125 (salmeterol 25 microgram, fluticasone propionate 125 microgram)
  • 25/250 (salmeterol 25 microgram, fluticasone propionate 250 microgram)

Further information
View Sirdupla drug record 
Summary of Product Characteristics
Manufacturer: Mylan

Sirdupla can be used in patients over 18 years of age not adequately controlled with inhaled corticosteroids and an 'as needed' inhaled short-acting β2-agonist, and in those already adequately controlled on both an inhaled corticosteroid and a long-acting β2-agonist.

The efficacy and safety of salmeterol and fluticasone for the treatment of asthma are well established.

Prescribers should note that only the AeroChamber Plus spacer device should be used with Sirdupla. 

Want news like this straight to your inbox?
Sign up for our bulletins

Read these next

Tiotropium: consider cardiovascular risk when prescribing

Tiotropium: consider cardiovascular risk when prescribing

Precautions for the use of tiotropium (Spiriva) in...

Colour change for Relvar Ellipta inhaler
Duaklir Genuair: new formoterol/aclidinium inhaler for COPD

Duaklir Genuair: new formoterol/aclidinium inhaler for COPD

Duaklir Genuair (formoterol fumarate dihydrate/aclidinium...

Ultibro Breezhaler: LABA/LAMA fixed-dose combination inhaler

Ultibro Breezhaler: LABA/LAMA fixed-dose combination inhaler

Novartis has launched Ultibro Breezhaler, a breath-actuated...

Incruse Ellipta: New once-daily inhaled antimuscarinic for COPD

Incruse Ellipta: New once-daily inhaled antimuscarinic for COPD

Incruse Ellipta (umeclidinium) is a once-daily long-acting...

First long-acting antimuscarinic approved for asthma

First long-acting antimuscarinic approved for asthma

Spiriva Respimat (tiotropium) is now indicated for...

Fostair NEXThaler: extrafine dry powder inhaler launched for asthma

Fostair NEXThaler: extrafine dry powder inhaler launched for asthma

Fostair NEXThaler (formoterol/beclometasone) is the...

Schools given permission to keep emergency salbutamol inhalers

Schools given permission to keep emergency salbutamol inhalers

From October 1st, primary and secondary schools in...

DuoResp Spiromax: new formoterol/budesonide inhaler

DuoResp Spiromax: new formoterol/budesonide inhaler

DuoResp Spiromax (formoterol/budesonide) has been launched...


Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases